Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Wants To Know What Doctors Know About Abuse-Deterrent Opioids

Executive Summary

Healthcare professionals will be asked about their knowledge of abuse-deterrent opioid formulations along with their views on prescription drug promotions.

You may also be interested in...



Rx Drug Ads: New US FDA Studies Target Accelerated Approval Information

Upcoming research projects will look at presentation of FDA approval status, timing of disease awareness ads, and healthcare professional views.

US FDA Chief Gottlieb Envisions Tiered Mandates For Opioid Training System

Mandatory training could be reserved for physicians who want to prescribe opioids for longer-term use, as opposed to those who would prescribe recommended amounts in blister packs; evidence that blister packs would affect prescribing still is needed, however.

Addiction Recovery Medications' 'Stigma' Needs To Be Eliminated, Gottlieb Says

US FDA commissioner tells House committee that culture changes – and label changes – are among the actions the agency is pursuing to address the opioid crisis.

Topics

UsernamePublicRestriction

Register

PS122717

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel